coronavirus
may
caus
respiratori
enter
central
nervou
system
diseas
mani
speci
includ
human
recent
rel
low
burden
diseas
human
caus
virus
hamper
develop
coronaviru
specif
therapeut
howev
emerg
sever
acut
respiratori
syndrom
coronaviru
sarscov
prompt
discoveri
drug
subsequ
studi
anim
model
demonstr
efficaci
sarscov
specif
monoclon
antibodi
sirna
sarscov
furthermor
sever
antivir
shown
effect
virus
test
vitro
avail
shown
efficaci
use
interferon
may
consid
sarscov
relat
coronaviru
emerg
recent
design
widespectrum
inhibitor
target
coronaviru
main
proteas
may
lead
discoveri
new
antivir
multipl
coronaviru
induc
diseas
coronavirus
posit
strand
rna
virus
name
corona
like
morpholog
appear
weiss
navasmartin
genom
largest
rna
genom
date
packag
togeth
nucleocapsid
protein
sever
membran
protein
e
sometim
hemagglutinin
esteras
protein
spike
protein
translat
correspond
author
tel
fax
replicas
gene
produc
two
larg
polyprotein
divers
enzymat
activ
need
effici
replic
phylogenet
analysi
replicas
gene
use
distantli
relat
toroviru
outgroup
demonstr
three
group
coronavirus
distinguish
despit
number
uniqu
featur
sever
acut
respiratori
syndrom
coronaviru
sarscov
close
relat
group
coronavirus
snijder
et
al
virus
belong
includ
transmiss
gastroenter
viru
pig
felin
infecti
periton
viru
cat
human
coronavirus
fig
sarscov
classifi
group
constitut
avian
coronavirus
infecti
bronchiti
viru
turkey
coronaviru
three
group
virus
classifi
thu
far
encod
set
uniqu
small
protein
unknown
function
coronavirus
caus
acut
chronic
respiratori
enter
central
nervou
system
diseas
mani
speci
includ
human
weiss
navasmartin
recent
need
develop
antivir
drug
limit
human
coronavirus
like
caus
mild
diseas
human
burden
diseas
known
present
howev
emerg
sar
chang
pictur
review
discuss
latest
develop
antivir
drug
test
specif
regard
sarscov
whenev
applic
broaden
scope
coronavirus
rang
compound
may
interfer
lifecycl
sarscov
shown
fig
discuss
sar
outbreak
affect
individu
worldwid
caus
fatal
lung
patholog
fatal
sar
show
bronchial
epitheli
denud
diffus
alveolar
damag
pneumocyt
hyperplasia
patient
die
late
cours
diseas
also
syncyti
cell
seen
alveoli
subsequ
three
laboratori
independ
report
isol
novel
coronaviru
clinic
specimen
sar
patient
peiri
et
al
ksiazek
et
al
viru
visual
electron
microscopi
identif
viru
accomplish
sequenc
differ
fragment
replicas
gene
obtain
randomprim
rtpcr
coronaviru
consensu
primer
importantli
sarscov
detect
lung
biopsi
bronchoalveolar
lavag
sar
patient
use
viru
cultur
rtpcr
electron
microscopi
wherea
viral
antigen
detect
alveolar
epitheli
cell
macrophag
immunohistolog
nichol
et
al
establish
sarscov
caus
diseas
koch
postul
fulfil
reproduct
diseas
relev
anim
model
infect
cynomolg
macaqu
sarscov
led
diseas
patholog
similar
seen
human
patient
sar
epitheli
necrosi
serosanguin
alveolar
exud
hyalin
membran
pneumocyt
hyperplasia
diffus
alveolar
damag
presenc
syncytia
kuiken
et
al
experi
also
led
develop
anim
model
test
efficaci
candid
vaccin
antivir
sar
characteris
rapidli
progress
atyp
pneumonia
refractori
convent
antibiot
therapi
next
effort
treat
sar
patient
mainli
base
use
ribavirin
corticosteroid
ribavirin
target
imp
dehydrogenas
known
long
time
broadspectrum
antivir
agent
howev
efficaci
sar
patient
remain
question
vitro
studi
also
show
signific
antivir
activ
cinatl
et
al
recent
studi
demonstr
ribavirin
even
enhanc
infect
sarscov
mice
barnard
et
al
collect
data
support
use
ribavirin
treat
sar
human
use
steroid
sar
patient
mainli
base
observ
clinic
deterior
observ
patient
late
diseas
sarscov
becam
undetect
case
concomit
use
drug
confound
result
fact
studi
contain
control
group
made
quit
difficult
determin
whether
steroid
exert
benefici
effect
although
effort
made
control
infect
use
antivir
corticosteroid
isol
quarantin
measur
eventu
prove
instrument
control
epidem
time
antibodi
sarscov
spike
protein
shown
block
entri
sui
et
al
sar
patient
recov
high
level
spike
glycoproteinspecif
antibodi
respons
observ
suggest
antibodi
respons
play
role
determin
ultim
diseas
outcom
sarscovinfect
patient
zhang
et
al
although
attempt
made
test
efficaci
serum
prepar
seroconvalesc
sar
patient
acut
phase
sar
conclus
evid
obtain
regard
efficaci
cheng
et
al
although
convalesc
immunoglobulin
exert
antivir
activ
given
macaqu
prior
sarscov
challeng
haagman
et
al
unpublish
observ
sarscov
spike
protein
bind
angiotensinconvert
enzym
act
function
receptor
sarscov
li
et
al
solubl
form
antibodi
block
interact
inhibit
sarscov
infect
region
within
spike
protein
specif
acid
fragment
protein
correspond
residu
identifi
region
interact
monoclon
antibodi
direct
domain
sarscov
spike
protein
shown
block
associ
sui
et
al
epitop
may
hidden
result
extens
glycosyl
balzarini
hypothes
drug
direct
carbohydr
compon
may
select
mutant
viru
strain
progress
gain
delet
glycosyl
site
uncov
previous
hidden
epitop
result
increas
immunolog
neutral
protect
efficaci
sarscov
neutral
antibodi
demonstr
convincingli
sever
anim
model
mice
effici
control
sarscov
infect
upon
passiv
transfer
serum
mice
recov
sarscov
infect
concept
antibodi
protect
sar
explor
gener
human
monoclon
antibodi
sarscov
prophylact
administr
monoclon
antibodi
mgkg
reduc
replic
sar
coronaviru
lung
infect
ferret
log
complet
prevent
develop
sar
coronavirusinduc
macroscop
lung
patholog
abolish
shed
viru
pharyng
secret
ter
meulen
et
al
monoclon
antibodi
evalu
efficaci
mouseand
hamstermodel
sui
et
al
robert
et
al
given
prophylact
mice
dose
therapeut
achiev
human
viral
replic
reduc
order
magnitud
assay
limit
post
exposur
treatment
also
allevi
viral
burden
associ
patholog
find
golden
syrian
hamster
model
sarscov
infect
hamster
treat
antibodi
viral
burden
reduc
tissuecultur
infecti
dose
per
gram
tissu
sever
associ
patholog
find
includ
interstiti
pneumon
consolid
also
remark
reduc
robert
et
al
traggiai
et
al
develop
effici
method
make
human
monoclon
sarscov
neutral
antibodi
memori
b
cell
result
prove
feasibl
immunoprophylaxi
use
human
monoclon
ab
provid
evid
vaccin
abl
elicit
neutral
antibodi
like
effect
sar
howev
demonstr
felin
coronaviru
antibodi
direct
coronaviru
spike
protein
sometim
enhanc
infect
macrophag
abl
take
felin
coronavirusantibodi
complex
effici
caus
viru
replic
higher
titer
passiv
activ
immun
felin
coronaviru
thu
may
enhanc
felin
coronaviru
infect
vivo
caus
earli
death
vennema
et
al
question
remain
whether
scenario
also
hold
sarscov
although
enhanc
entri
certain
sarscov
pseudotyp
virus
vero
cell
observ
presenc
antibodi
direct
spike
protein
yang
et
al
relev
vivo
still
await
investig
thu
caution
taken
account
develop
strategi
block
sarscov
entri
antibodi
engag
sarscov
fuse
host
cell
membran
fusion
mechan
similar
exert
class
fusion
protein
conform
chang
two
heptad
region
locat
region
caus
format
oligomer
structur
lead
fusion
viral
targetcel
membran
therefor
block
interact
may
reveal
novel
strategi
inhibit
entri
sarscov
inde
synthet
peptid
deriv
region
bind
high
affin
peptid
region
interfer
conform
chang
lead
bundl
format
subsequ
block
sarscov
infect
zhu
et
al
liu
et
al
bosch
et
al
ni
et
al
howev
rel
low
efficaci
may
hamper
develop
sarscov
antivir
moment
recent
observ
demonstr
besid
conform
chang
interact
lysosom
cystein
proteas
requir
product
infect
sarscov
util
cathepsin
l
infect
cell
inhibitor
cathepsin
l
like
calpain
inhibitor
iii
vi
block
sarscov
infect
simmon
et
al
huang
et
al
moment
exact
mechan
action
enzym
clear
sarscov
enter
cell
fuse
cellular
membran
posit
strand
coronaviru
genom
releas
viral
replic
initi
howev
subsequ
format
doubl
strand
rna
intermedi
strong
trigger
innat
immun
respons
interact
tolllik
receptor
product
type
interferon
ifn
initi
limit
viral
replic
interestingli
sever
studi
demonstr
ifn
product
sarscov
infect
cell
may
limit
macrophag
well
cell
infect
sarscov
show
induct
ifnbeta
gene
express
cheung
et
al
spiegel
et
al
therefor
sarscov
like
encod
viral
protein
interfer
one
signal
cascad
lead
product
type
ifn
cell
hand
sarscov
remain
sensit
action
exogen
ifn
sever
studi
note
ifn
inhibit
replic
sarscov
cell
cultur
vitro
potent
either
cinatl
et
al
haagman
et
al
hensley
et
al
stroher
et
al
conjunct
synergist
inhibit
replic
sarscov
sainz
et
al
similarli
ifn
inhibit
replic
anim
human
coronavirus
turner
et
al
smith
et
al
pei
et
al
virus
caus
lysi
target
cell
effect
inhibit
ifn
antivir
activ
noninfect
cell
therefor
ifn
highest
util
prophylaxi
earli
postexposur
manag
sar
pegyl
shown
effect
reduc
viral
replic
excret
viral
antigen
express
type
pneumocyt
pulmonari
damag
cynomolg
macaqu
infect
experiment
sarscov
evid
protect
effect
ifnalpha
also
obtain
preliminari
studi
sar
outbreak
interferon
combin
corticosteroid
loutfi
et
al
ifn
commerci
avail
treatment
hepat
b
c
drug
could
consid
treatment
sar
reemerg
rna
interfer
rnai
provid
effect
antivir
defenc
plant
organ
sever
studi
focus
har
rnai
inhibit
viral
infect
leonard
schaffer
explor
possibl
interrupt
sarscoronaviru
replic
sirna
specif
sirna
target
spike
gene
sar
coronaviru
synthesis
sirna
effect
specif
inhibit
gene
express
spike
protein
sarscoronavirusinfect
cell
zhang
et
al
anoth
studi
assess
vitro
efficiaci
six
sirna
molecul
target
differ
site
replicas
region
sarscoronaviru
genom
et
al
judg
morpholog
chang
three
molecul
markedli
inhibit
cytopath
effect
caus
viral
infect
replic
three
sirna
also
inhibit
infect
replic
differ
strain
sar
coronaviru
indic
sirna
target
replicas
region
may
option
futur
clinic
use
potent
sirna
inhibitor
sarscov
vitro
target
sarscov
genom
proteinand
region
evalu
efficaci
rhesu
macaqu
sar
model
found
provid
relief
sarscov
infectioninduc
fever
diminish
sarscov
level
reduc
acut
diffus
alveolar
damag
pivot
role
play
coronaviru
main
proteas
control
viral
replic
transcript
extens
process
replicas
polyprotein
togeth
absenc
close
relat
cellular
homologu
identifi
protein
potenti
import
target
antivir
drug
design
sarscov
encod
main
proteas
cleav
replicas
polyprotein
conserv
site
order
gener
function
protein
necessari
viru
replic
crystal
structur
sarscov
main
proteas
complex
variou
substrat
analogu
determin
recent
yang
et
al
report
discoveri
highli
conserv
region
base
four
crystal
structur
one
homolog
model
main
proteas
repres
three
genet
cluster
genu
coronaviru
furthermor
reveal
uniform
inhibit
mechan
structur
main
proteaseinhibitor
complex
sarscov
tgev
structureassist
optim
program
yield
compound
fast
vitro
inactiv
multipl
cov
main
proteas
potent
antivir
activ
extrem
low
cellular
toxic
cellbas
assay
modif
could
rapidli
lead
discoveri
singl
agent
clinic
potenti
exist
possibl
futur
emerg
covassoci
diseas
also
main
proteas
inhibitor
shown
inhibit
sarscov
replic
vitro
cinanserin
niclosamid
anilid
pheph
dipeptid
inhibitor
found
inhibit
main
proteas
inhibit
viru
replic
vero
cell
shie
et
al
chen
et
al
lopinavirritonavir
combin
first
consid
potenti
use
treatment
vitro
studi
show
antivir
activ
sarscov
chan
et
al
compar
outcom
peopl
receiv
lopinavirritonavir
initi
treatment
rescu
therapi
match
control
patient
given
ribavirin
steroid
accord
standardis
protocol
addit
lopinavirritonavir
initi
treatment
associ
statist
signific
reduct
overal
death
rate
intub
rate
compar
match
control
chu
et
al
also
assess
treatment
lopinavirritonavir
compar
histor
control
patient
also
treat
ribavirin
steroid
similar
protocol
chan
colleagu
advers
event
develop
acut
respiratori
distress
syndrom
ard
death
within
day
significantli
lower
lopinavirritonavir
group
histor
control
addit
signific
reduct
need
rescu
puls
steroid
sever
respiratori
deterior
significantli
lower
nosocomi
infect
also
note
treat
lopinavirritonavir
compar
control
multivari
analysi
demonstr
lack
treatment
lopinavirritonavir
age
year
old
greater
posit
hepat
b
carrier
statu
independ
predictor
advers
outcom
includ
death
develop
ard
requir
intens
care
within
day
onset
ill
base
studi
lopinavirritonavir
appear
promis
antisarscov
agent
proteas
inhibitor
studi
vitro
potenti
antivir
effect
sar
exampl
yamamoto
et
al
screen
set
compound
includ
antivir
drug
alreadi
wide
use
found
nelfinavir
strongli
inhibit
sarscov
replic
addit
calpain
inhibitor
vi
valleucho
calpain
inhibitor
iii
zvalphealacho
inhibit
sarscov
barnard
et
al
suggest
proteas
inhibitor
may
also
use
treatment
sar
larg
number
compound
inhibit
sarscov
replic
unknown
mechan
action
identifi
glycyrrhizin
consist
one
molecul
glycyrrhetin
acid
link
two
molecul
glucuron
acid
known
exert
antivir
activ
rang
virus
also
inhibit
sarscov
replic
although
rel
high
concentr
need
cinatl
et
al
mechan
glycyrrhizininduc
inhibit
viral
replic
specif
sarscov
replic
unclear
possibl
involv
inhibit
replic
antivir
effect
nitric
oxid
sarscov
replic
inhibit
deta
nonoat
donor
compound
ad
cultur
medium
cinatl
et
al
inhibit
sarscov
infect
vitro
also
report
nitric
oxid
gener
compound
snitrosonacetylpenicillamin
snap
high
concentr
keyaert
et
al
wide
varieti
pyridin
noxid
deriv
found
inhibitori
felin
coronaviru
fipv
strain
human
sarscov
frankfurt
crfk
simian
kidney
vero
cell
cultur
respect
balzarini
et
al
bananin
shown
inhibit
atpas
helicas
activ
sarscov
inhibit
sarscov
replic
vitro
tanner
et
al
chloroquin
best
known
antimalari
effect
recommend
potenti
use
prefer
combin
antivir
treatment
sar
keyaert
et
al
chloroquin
inhibit
sarscov
replic
vero
cell
ec
approxim
plasma
concentr
chloroquin
reach
treatment
acut
malaria
final
wu
et
al
test
agent
sarscov
vero
cell
select
approxim
activ
compound
valinomycin
peptid
insecticid
act
potassium
ion
transport
potent
inhibitor
